Antimitochondrial

Antimitochondrial refers to antibodies that target components of mitochondria, the organelles responsible for cellular energy production. The presence of antimitochondrial antibodies (AMAs) in the blood is a significant diagnostic marker for certain autoimmune diseases.

The most well-known association of AMAs is with primary biliary cholangitis (PBC), a chronic liver disease characterized by the progressive destruction of small and medium-sized bile ducts. In PBC, AMAs typically target the pyruvate dehydrogenase complex (PDC-E2), a key enzyme in mitochondrial metabolism. While PBC is the primary condition linked to AMAs, they can occasionally be found in other autoimmune disorders like Sjögren's syndrome and systemic lupus erythematosus, though usually at lower titers and with different target specificities.

The detection of AMAs is usually performed through enzyme-linked immunosorbent assay (ELISA) or indirect immunofluorescence. A positive AMA test, particularly in the context of compatible clinical symptoms, strongly suggests PBC. However, a positive AMA test alone does not confirm a diagnosis, and further investigations are often necessary. The exact mechanism by which AMAs contribute to disease pathogenesis is still under investigation, but it is believed to involve an immune-mediated attack on mitochondrial components, leading to cellular damage and inflammation.